Patents Examined by Sheela Huff
  • Method for treating cancers which present antigen FB5 with humanized antibodies
    Patent number: 6391302
    Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: May 21, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
  • DNA for evaluating the progression potential of cervical lesions
    Patent number: 6388065
    Abstract: The present invention relates to a nucleic acid which is suitable for evaluating the progression potential of cervial lesions, wherein the nucleic acid is obtainable by a process in which RNA from early and late passages of HPV-immortalized cells is isolated and the RNAs characteristic for the early passages and late passages, respectively, are identified and provided as DNA or RNA. Furthermore, the present invention concerns polypeptides coded by such a nucleic acid. In addition, it covers antibodies directed against the polypeptides. Moreover, it relates to the use of the DNA and the polypeptides as well as a kit suitable for evaluating the progression of cervical lesions.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: May 14, 2002
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Matthias Dürst, Matthias Nees
  • Non-invasive method to detect prostate cancer
    Patent number: 6383759
    Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: May 7, 2002
    Assignee: Gerald P. Murphy Cancer Foundation
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, Robert J. Barren, III
  • Method for enhancing immune responses in mammals
    Patent number: 6379708
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.
    Type: Grant
    Filed: November 20, 1999
    Date of Patent: April 30, 2002
    Assignees: Cytologic, LLC, Colorado State University Research Foundation
    Inventors: Mark Douglas Howell, Cheryl Lynn Selinsky, Leland Charles Leber
  • Diagnostic method using expression of MN/CA9 protein in AGUS Pap smears
    Patent number: 6379907
    Abstract: Determining the presence of cancerous or pre-cancerous cervical lesions from AGUS-diagnosed Pap smear cells by observing the distribution of MN/CA9 antigen expressed on atypical or normal cells and diagnosing (a) significant lesions when MN/CA9 antigen is observed on atypical cells, (b) low grade lesions when MN/CA9 antigen is absent from atypical cells but is present on normal endocervical cells, and (c) a benign condition when MN/CA9 antigen is absent from both atypical cells and normal endocervical cells.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: April 30, 2002
    Assignee: The Regents of the University of California
    Inventors: Shu-Yuan Liao, Eric J. Stanbridge
  • Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
    Patent number: 6376654
    Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies and binding fragments thereto capable of being used for therapeutic, diagnostic, and cell purification purposes.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: April 23, 2002
    Assignee: Molecular Discoveries, LLC
    Inventor: Cohava Gelber
  • Tie2 antagonist antibodies
    Patent number: 6376653
    Abstract: Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: April 23, 2002
    Assignees: SmithKline Beecham plc, SmithKline Beecham Corporation
    Inventors: Stephen D. Holmes, Connie L. Erickson-Miller, James D. Winkler
  • Method for diagnosis and therapy of Hodgkin's lymphomas
    Patent number: 6372441
    Abstract: The invention relates to a method for diagnosing and treating Hodgkin's lymphomas (lymphogranulomatosis) which is based on the expression of the variant exon v10 of the CD44 gene as a molecular marker or target. There is a significant correlation between v10 expression and the stage and prognosis of the disease. In a preferred embodiment, v10-specific antibody molecules are used to measure the expression of the exon in samples. In another preferred embodiment, radiolabelled v10-specific antibodies are used to treat Hodgkin's lymphomas.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: April 16, 2002
    Assignees: Forschungszentrum Karlsruhe GmbH, Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Kurt Zatloukal, Christine Beham-Schmid
  • Glutathione S-transferase homolog
    Patent number: 6368810
    Abstract: The invention provides a human glutathione S-transferase (GSTH) and polynucleotides which identify and encode GSTH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of GSTH.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: April 9, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Peptides for the production of preparations for the diagnosis and therapy of systemic lupus
    Patent number: 6369203
    Abstract: Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187-211 and the N termini of H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of SLE is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of SLE.
    Type: Grant
    Filed: September 16, 1992
    Date of Patent: April 9, 2002
    Assignee: Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologic mbH
    Inventors: Michael Zeppezauer, Arno Schönberger, Ladislav Cebecauer
  • Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 &agr; subunit
    Patent number: 6365712
    Abstract: Isolated proteins comprising the T-cell surface antigen CD97 &agr; are provided. Compositions and methods for making and detecting CD97 &agr; are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: April 2, 2002
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Kathleen Kelly
  • Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
    Patent number: 6365357
    Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: April 2, 2002
    Assignee: Onotech, Inc.
    Inventors: Eugene Mechetner, John Fruehauf
  • Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
    Patent number: 6358922
    Abstract: This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: March 19, 2002
    Assignee: Medical University of South Carolina
    Inventor: Thomas A. Dix
  • Compounds
    Patent number: 6359116
    Abstract: HE8AN36 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HE8AN36 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: March 19, 2002
    Assignee: SmithKline Beecham plc
    Inventor: Stephen L Mathias
  • H-rev107-like protein
    Patent number: 6359123
    Abstract: The present invention provides a human H-rev107-like protein (HREVP) and polynucleotides which identify and encode HREVP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HREVP and a method for producing HREVP. The invention also provides for agonists, antibodies, or antagonists specifically binding HREVP, and their use, in the prevention and treatment of diseases associated with expression of HREVP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HREVP for the treatment of diseases associated with the expression of HREVP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HREVP.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: March 19, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Reagents and methods useful for detecting diseases of the prostate
    Patent number: 6350583
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS190 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS190-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS190 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: February 26, 2002
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Edward N. Granados, Michael R. Klass, John C. Russell, Stephen D. Stroupe
  • Antibodies with increased binding affinity
    Patent number: 6350861
    Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: February 26, 2002
    Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
  • Method for treating a catecholamine secretion
    Patent number: 6350455
    Abstract: A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: February 26, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays
    Patent number: 6350572
    Abstract: The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: February 26, 2002
    Assignee: Prolifix Limited
    Inventors: René Bernards, Renate Zwijsen
  • Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
    Patent number: 6350860
    Abstract: The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: February 26, 2002
    Assignee: Innogenetics N.V.
    Inventors: Marie-Ange Buyse, Erwin Sablon